

Alberto Floris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6775962/publications.pdf>

Version: 2024-02-01

40
papers

775
citations

623699

14
h-index

526264

27
g-index

41
all docs

41
docs citations

41
times ranked

1126
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. <i>Rheumatology</i> , 2018, 57, 227-235.	1.9	101
2	Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort. <i>Autoimmunity Reviews</i> , 2014, 13, 873-879.	5.8	71
3	Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2017, 19, 247.	3.5	66
4	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <i>Mediators of Inflammation</i> , 2018, 2018, 1-11.	3.0	56
5	The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. <i>Rheumatology</i> , 2018, 57, 112-119.	1.9	53
6	Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. <i>Autoimmunity Reviews</i> , 2016, 15, 656-663.	5.8	51
7	Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. <i>Autoimmunity Reviews</i> , 2017, 16, 244-252.	5.8	41
8	Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 190-198.	1.6	39
9	Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. <i>Rheumatology</i> , 2020, 59, 3622-3632.	1.9	39
10	Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. <i>Lupus</i> , 2016, 25, 28-37.	1.6	28
11	Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. <i>Clinical Rheumatology</i> , 2022, 41, 19-31.	2.2	28
12	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. <i>Rheumatology</i> , 2020, 59, 2272-2281.	1.9	25
13	Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic. <i>Rheumatology</i> , 2022, 61, 1795-1801.	1.9	22
14	Polymyalgia rheumatica: an autoinflammatory disorder?. <i>RMD Open</i> , 2018, 4, e000694.	3.8	15
15	Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage. <i>Arthritis Care and Research</i> , 2020, 72, 1794-1799.	3.4	13
16	Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001-2012. <i>Rheumatology International</i> , 2016, 36, 73-81.	3.0	12
17	Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. <i>Reumatismo</i> , 2017, 69, 175-183.	0.9	12
18	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group. <i>European Journal of Internal Medicine</i> , 2022, 96, 60-65.	2.2	12

#	ARTICLE	IF	CITATIONS
19	Killerâ€Cell Immunoglobulinâ€Like Receptors (<sc>KIR</sc>) and <sc>HLA</sc>â€Class <sc>I</sc> Heavy Chains in Ankylosing Spondylitis. Drug Development Research, 2014, 75, S15-9.	2.9	11
20	New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol. Journal of rheumatology Supplement, The, 2015, 93, 70-72.	2.2	10
21	Physicianâ€™s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. Journal of Rheumatology, 2018, 45, 1256-1262.	2.0	10
22	Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis). ImmunoTargets and Therapy, 2015, 4, 185.	5.8	9
23	Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis. RMD Open, 2018, 4, e000597.	3.8	9
24	Discordance between patient and physician global assessment of disease activity in Behçetâ€™s syndrome: a multicenter study cohort. Arthritis Research and Therapy, 2020, 22, 278.	3.5	7
25	Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs. Medicine (United States), 2021, 100, e25481.	1.0	7
26	Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoudâ€™s arthropathy and a distinctive MRI pattern. Rheumatology, 2021, 60, 4218-4228.	1.9	5
27	Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 167-170.	1.6	4
28	AIF-1 gene does not confer susceptibility to Behçetâ€™s disease: Analysis of extended haplotypes in Sardinian population. PLoS ONE, 2018, 13, e0204250.	2.5	4
29	Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease. Rheumatology, 2017, 56, 2038-2039.	1.9	2
30	<p>Assessment Of Circulating Endothelial Cells And Their Progenitors As Potential Biomarkers Of Disease Activity And Damage Accrual In Behçetâ€™s Syndrome<p>, Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 219-227.	1.6	2
31	Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review. BioDrugs, 2021, 35, 175-186.	4.6	2
32	Gene Expression Profiling of Monozygotic Twins Affected by Psoriatic Arthritis. Open Access Rheumatology: Research and Reviews, 2021, Volume 13, 23-29.	1.6	2
33	Targeted Therapies in Axial Psoriatic Arthritis. Frontiers in Genetics, 2021, 12, 689984.	2.3	1
34	Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity. Rheumatology, 2022, 62, 116-123.	1.9	1
35	277â€fUsing the Birmingham Vasculitis Activity Score as a Screening Tool in Patients with Suspected Vasculitis. Rheumatology, 0, , .	1.9	0
36	THU0299â€...PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHçETâ€™S SYNDROME: A MULTICENTER STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	SAT0035â€¦...IS PHARMACOLOGICAL CLINICAL REMISSION SYNONYMOUS WITH BIOLOGICAL INACTIVE DISEASE? DIFFERENTIAL GENE EXPRESSION ANALYSIS IN RHEUMATOID ARTHRITISAND HEALTHY CONTROLS. , 2019, , .		0
38	SAT0240â€¦...DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÃ†ETÃ€™S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .		0
39	FRI0357â€¦...DRUG-INDUCED REMISSION AND SUBCLINICAL ACTIVITY IN PSORIATIC ARTHRITIS: TRANSCRIPTIONAL PROFILING TO CHARACTERIZETHE DISEASE STATE. , 2019, , .		0
40	THU0095â€¦...CIGARETTE SMOKING AS PREDICTOR OF INADEQUATE RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITISPATIENTS NAÃ†VE TO DMARDS. , 2019, , .		0